Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891363713> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2891363713 abstract "11523 Background: Bev is a monoclonal antibody that binds to VEGFA that demonstrated improved progression free survival (PFS) in MBC clinical trials. VEGFR2, NOTCH1, Integrin a1b2 and ILK are angiogenesis-related proteins possibly related with Bev efficacy. The correlation of these proteins expression and Bev survival variables was evaluated. Methods: We retrospectively analyzed 1 st line chemotherapy in two HER2 negative MBC cohorts. Pts were treated between May-07 and July-14. Cohort 1 (C1) was treated with paclitaxel and Cohort 2 (C2) with paclitaxel and Bev. Expression of biomarkers was determined by immunohistochemistry. Tumor samples were arranged on a tissue microarray. Survival curves were calculated by Kaplan-Meier method and log-rank test. Cox model was used in multivariate analysis. Results: C1 had 42 pts. Median age was 63y. Tumor subtypes were divided in luminal (92.9%) and triple negative (TN) (7.1%). Visceral metastasis (mets) were present in 71.4%. Median follow-up (mFUP) time was 32.1m. mPFS was 8.0m and mOS was 33.5m. C2 had 29 pts. Median age was 57y. Luminal 79.3%; TN 20.7%; Visceral mets 79.3%; mFUP 38m. mPFS was 10.5m and mOS was 47m. In C2, high VEGFR2ce was correlated with improved PFS (high VEGFR2 16.5m x low VEGFR2 6.8m, p = 0.025). Breast cancer subtype, metastasis pattern and VEGFR2 expression were included in the multivariate analysis for PFS. VEGFR2 remained as independent factor (HR 0.35; IC95% 0.14 – 0.85, p = 0.021). In C1, VEGFR2 was not correlated with improved PFS (high VEGFR2 8.6m x low VEGFR2 8.0m, p = 0.24). Other markers were not associated with PFS. Conclusions: High VEGFR2ce was associated with increased PFS in patients treated with Bev. In MBC VEGFR2 may have a role as a predictive tool on benefit of antiangiogenic therapy." @default.
- W2891363713 created "2018-09-27" @default.
- W2891363713 creator A5000078886 @default.
- W2891363713 creator A5005241227 @default.
- W2891363713 creator A5007982458 @default.
- W2891363713 creator A5008152833 @default.
- W2891363713 creator A5010474480 @default.
- W2891363713 creator A5022202861 @default.
- W2891363713 creator A5055743219 @default.
- W2891363713 creator A5056069103 @default.
- W2891363713 date "2017-05-20" @default.
- W2891363713 modified "2023-09-27" @default.
- W2891363713 title "VEGFR2 cytoplasmic expression (VEGFR2ce) in relation to survival in metastatic breast cancer (MBC) patients (pts) treated with bevacizumab (Bev)." @default.
- W2891363713 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.11523" @default.
- W2891363713 hasPublicationYear "2017" @default.
- W2891363713 type Work @default.
- W2891363713 sameAs 2891363713 @default.
- W2891363713 citedByCount "0" @default.
- W2891363713 crossrefType "journal-article" @default.
- W2891363713 hasAuthorship W2891363713A5000078886 @default.
- W2891363713 hasAuthorship W2891363713A5005241227 @default.
- W2891363713 hasAuthorship W2891363713A5007982458 @default.
- W2891363713 hasAuthorship W2891363713A5008152833 @default.
- W2891363713 hasAuthorship W2891363713A5010474480 @default.
- W2891363713 hasAuthorship W2891363713A5022202861 @default.
- W2891363713 hasAuthorship W2891363713A5055743219 @default.
- W2891363713 hasAuthorship W2891363713A5056069103 @default.
- W2891363713 hasConcept C121608353 @default.
- W2891363713 hasConcept C126322002 @default.
- W2891363713 hasConcept C143998085 @default.
- W2891363713 hasConcept C2775930923 @default.
- W2891363713 hasConcept C2776694085 @default.
- W2891363713 hasConcept C2777802072 @default.
- W2891363713 hasConcept C530470458 @default.
- W2891363713 hasConcept C71924100 @default.
- W2891363713 hasConceptScore W2891363713C121608353 @default.
- W2891363713 hasConceptScore W2891363713C126322002 @default.
- W2891363713 hasConceptScore W2891363713C143998085 @default.
- W2891363713 hasConceptScore W2891363713C2775930923 @default.
- W2891363713 hasConceptScore W2891363713C2776694085 @default.
- W2891363713 hasConceptScore W2891363713C2777802072 @default.
- W2891363713 hasConceptScore W2891363713C530470458 @default.
- W2891363713 hasConceptScore W2891363713C71924100 @default.
- W2891363713 hasLocation W28913637131 @default.
- W2891363713 hasOpenAccess W2891363713 @default.
- W2891363713 hasPrimaryLocation W28913637131 @default.
- W2891363713 hasRelatedWork W1994655768 @default.
- W2891363713 hasRelatedWork W2009786335 @default.
- W2891363713 hasRelatedWork W2130426922 @default.
- W2891363713 hasRelatedWork W2138034193 @default.
- W2891363713 hasRelatedWork W2240804564 @default.
- W2891363713 hasRelatedWork W2241514289 @default.
- W2891363713 hasRelatedWork W2245904712 @default.
- W2891363713 hasRelatedWork W2275569918 @default.
- W2891363713 hasRelatedWork W2280647462 @default.
- W2891363713 hasRelatedWork W2415433510 @default.
- W2891363713 hasRelatedWork W2485554651 @default.
- W2891363713 hasRelatedWork W2567887715 @default.
- W2891363713 hasRelatedWork W2590150925 @default.
- W2891363713 hasRelatedWork W2591120038 @default.
- W2891363713 hasRelatedWork W2591166930 @default.
- W2891363713 hasRelatedWork W2599729604 @default.
- W2891363713 hasRelatedWork W2601990098 @default.
- W2891363713 hasRelatedWork W2942043208 @default.
- W2891363713 hasRelatedWork W2950824293 @default.
- W2891363713 hasRelatedWork W2934037562 @default.
- W2891363713 isParatext "false" @default.
- W2891363713 isRetracted "false" @default.
- W2891363713 magId "2891363713" @default.
- W2891363713 workType "article" @default.